Showing results (491-500 of 556) with videos related to
Sort By:
Pageof 56
Cardiovascular Revascularization Medicine : Including Molecular Interventions|May 9, 2022
Clinical Outcomes and OCT Analysis After Culotte Stenting With 2nd- and 3rd-Generation Everolimus-Eluting Stents: Two-Year Follow-Up of the CELTIC Bifurcation StudyCalum Creaney, Simon J Walsh, Colm G Hanratty, et al.Journal of the American College of Cardiology|January 22, 2003
Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experienceMuzaffer Degertekin, Evelyn Regar, Kengo Tanabe, et al.International Journal of Cardiovascular Interventions|March 8, 2003
First clinical experience with the R Stent: a new highly flexible stainless steel tube intracoronary stentMichael JB Kutryk, Alexander J Wardeh, Arie HM Knook, et al.American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 10, 2022
Cross-decoration of dendritic cells by non-inherited maternal antigen-containing extracellular vesicles: Potential mechanism for PD-L1-based tolerance in cord blood and organ transplantationDiego A Lema, Ewa Jankowska-Gan, Ashita Nair, et al.Orbit (Amsterdam, Netherlands)|March 16, 2017
Management of thyroid eye disease in the United Kingdom: A multi-centre thyroid eye disease auditF E Mellington, C M Dayan, A J Dickinson, et al.Annals of Surgery|October 26, 2005
Simultaneous pancreas-kidney transplantation from donation after cardiac death: successful long-term outcomesLuis A Fernandez, Antonio Di Carlo, Jon S Odorico, et al.Annals of Surgery|October 26, 2005
Donation after cardiac death: the University of Wisconsin experience with liver transplantationDavid P Foley, Luis A Fernandez, Glen Leverson, et al.The Journal of Pharmacology and Experimental Therapeutics|August 10, 2017
Characterization of the Potent, Selective Nrf2 Activator, 3-(Pyridin-3-Ylsulfonyl)-5-(Trifluoromethyl)-2H-Chromen-2-One, in Cellular and In Vivo Models of Pulmonary Oxidative StressJohn G Yonchuk, Joseph P Foley, Brian J Bolognese, et al.Molecular Cancer Therapeutics|December 7, 2011
Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapyWeiwen Ying, Zhenjian Du, Lijun Sun, et al.The Journal of Invasive Cardiology|July 30, 2004
Clinical and angiographic safety and efficacy trial with a new coronary stent: the RESTOR study of the R StentPeter den Heijer, Benno J W M Rensing, David P Foley, et al.Pageof 56